3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Carcinoma, Non-Small-Cell Lung
6
Melanoma
4
Carcinoma, Renal Cell
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Neoplasms
2
Mesothelioma
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Bile Duct Neoplasms
2
Vulvar Neoplasms
1
Uveal Melanoma
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Parotid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Interventions
enfortumab vedotin
2
pembrolizumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Urethral Neoplasms
×
pembrolizumab
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA